Show notes
Also: Ollama adds local text-to-speech for Mac AI apps
On October 23, Pathos AI said Bristol Myers Squibb and Tempus are joining it on a new AI drug-development program that starts with Alzheimer’s disease and other neurological conditions. Tempus will assemble a large de-identified patient dataset, and Pathos will use its Foundry system to test ideas about disease progression and clinical trial design at scale. Bristol Myers also led a $237 million Pathos funding round tied to the deal. The practical point is that AI is moving deeper into the expensive middle of drug development, where…
Website: spreaker.com

